Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ayesha Rashid

Psychiatry Houston, TX Medical Doctor

NPI 1942447610 CMS profile 133277

1110 Nasa Pkwy Ste 620, Houston, TX 77058

Open in the dashboard

General payments

$641,122

1,696 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ayesha Rashid of Houston, TX is reported in the CMS Open Payments database as having received $641,122 across 1,696 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $209,424 389
2024 General $150,142 291
2023 General $102,269 308
2022 General $85,135 296
2021 General $53,018 212
2020 General $10,922 47
2019 General $30,212 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ayesha Rashid
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Ayesha Rashid were reported at $209,424. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Ayesha Rashid Psychiatry median Middle half National median
2019 $30,212 $184 $59–$605 $163
2020 $10,922 $119 $36–$372 $114
2021 $53,018 $143 $43–$576 $132
2022 $85,135 $153 $50–$590 $149
2023 $102,269 $170 $56–$651 $160
2024 $150,142 $179 $57–$673 $164
2025 $209,424 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $182,707 285 payments
  2. AbbVie, Inc. $176,172 294 payments
  3. Corium, Inc. $164,689 295 payments
  4. Axsome Therapeutics, Inc. $57,782 74 payments
  5. Sunovion Pharmaceuticals Inc. $41,067 114 payments
  6. Neos Therapeutics, LP $5,569 93 payments
  7. Neuronetics, Inc. $2,032 20 payments
  8. Supernus Pharmaceuticals, Inc. $1,558 86 payments
  9. Teva Pharmaceuticals USA, Inc. $1,261 45 payments
  10. Janssen Pharmaceuticals, Inc $1,231 62 payments
  11. Other $7,054 328 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $423,884 200 payments
  2. Travel and Lodging $120,318 308 payments
  3. Consulting Fee $46,690 17 payments
  4. Food and Beverage $29,871 1,155 payments
  5. Honoraria $19,663 6 payments
  6. Education $697 10 payments
Products named General payments · program years 2019–2025
  1. Azstarys $164,689 295 payments
  2. CAPLYTA Psychiatry $113,682 151 payments
  3. VRAYLAR Neuroscience $106,225 206 payments
  4. CAPLYTA Psychiatry $69,025 134 payments
  5. VRAYLAR Neuroscience $64,745 88 payments
  6. Auvelity $57,782 74 payments
  7. LATUDA $41,067 114 payments
  8. COTEMPLA XR-ODT $5,021 57 payments
  9. Adzenys XR-ODT $4,817 47 payments
  10. NEUROSTAR TMS THERAPY $1,997 17 payments
  11. Other $11,620 559 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

69

Median for Psychiatry & Neurology: 100

Drug cost

$4,486

Median for Psychiatry & Neurology: $2,986

Branded share of claims

0%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lisdexamfetamine Dimesylate Generic 14 $3,955
Escitalopram Oxalate Generic 23 $343
Trazodone Hcl Generic 20 $131
Methylphenidate Hcl Generic 12 $58

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$73,168 — —
CAPLYTA
$55,007 — —
Auvelity
$16,631 — —
Azstarys
$4,075 — —
Qelbree
$218 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

1,696 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record